12% organic growth, EBITA margin of 15.1% (14.1%) Increased financial targets Positive estimate revi...
Announced share issue to support its growth strategy.
Net profit in Q1 18% above ABGSCe driven by... ...loan loss reversals and investment portfolio earni...
Following BankNordik's Q1 report, we lift 2023E adjusted EPS by ~3% to reflect the continued solid a...
Ahead of Taaleri's Q1, due on 3 May, we maintain our underlying estimates but adjust for the IFRS 17...
Fiskars' Q1 was characterised by low demand due to high retailers' inventories and healthy gross mar...
Redeye återkommer med en update efter BioArctics Q1-rapport och ytterligare framsteg för Lecanemab.
Redeye provides its initial take on Heliospectra’s Q1’23 report, stating that sales and order intake...
Sales +12% vs ABGSCe, adj. EBITA +4% vs ABGSCe Soft near-term margin outlook, adj.
Redeye expects neutral or slightly positive revisions of our Base Case and estimates following Fortn...
Redeye states that Addnode had another solid quarter where sales and EBITA beat our forecasts.
Redeye’s first comments following this morning’s Q1 report from Tagmaster.
Redeye comments on AVTECH's Q1'23 report which was slightly below estimates on net sales while bette...
Mixed results with stronger adj. EBITA but softer net income Implied revisions: adj.
Rovio reported Q1 revenue 2% below Modular Finance consensus and adjusted EBIT bang in line.
Redeye states that Doro’s Q1 2023 report was weaker than Redeyes expectation due to lower sales and ...
Q1 NOI 0% vs ABGSCe Property value changes -1.8% vs ABGSCe -1.
We cut '23e-'25e ARR by 1% ARR growth streak untouched EV/ARR 2.
Redeye retains its positive view of Efecte following a Q1 largely matching our forecasts.
Q1'23 sales -19% vs. ABGSCe Increased accounting transparency We cut '23e-'25e sales by 18-7% Q1'23...
